{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:50:43Z","timestamp":1793922643741,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fabry disease is a lysosomal storage disorder caused by deficient activity of the enzyme \u03b1-galactosidase A, resulting in progressive accumulation of globotriaosylceramide (Gb3) and widespread tissue and organ damage. Enzyme replacement therapy (ERT) can slow disease progression but may elicit antidrug antibody (ADA) responses. The impact of ADA status on long-term ERT efficacy and safety remains incompletely understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We conducted a systematic literature review (SLR) to examine the impact of ADA status on outcomes in patients with Fabry disease receiving ERT. We aimed to evaluate associations between ADA status and specific outcomes, and to identify remaining evidence needs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic searches were conducted in MEDLINE and Embase (up to March 4, 2025), supplemented by searches of the Cochrane Library and clinical trial registries. Eligible publications reported data on the relationship between ADA status and Fabry disease-related biomarkers (Gb3, globotriaosylsphingosine [lyso-Gb3]), efficacy (renal and cardiovascular) outcomes, and safety (adverse events [AEs] and infusion-related reactions [IRRs]) outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 1763 articles screened, 24 were included (19 reported disease-related biomarkers, 10 renal outcomes, 4 cardiovascular, and 9 AE\/IRR data). Most analyses of disease-related biomarkers (17\/18) reported statistically significant positive associations (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) between ADA positivity and elevated biomarkers: plasma lyso-Gb3 (4\/8 studies), plasma Gb3 (1\/3 studies), and urine Gb3 (6\/6 studies). Some renal data sets (2\/9) reported evidence suggesting a potential association between more rapid decline in estimated glomerular filtration rate in ADA-positive (vs ADA-negative) patients. Four out of 9 studies reported statistically significant associations between ADA positivity and IRR occurrence; most studies stratifying IRR rates by ADA status (5\/7) reported higher rates among ADA-positive (vs ADA-negative) subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This SLR found evidence that ADA positivity may be associated with increased IRR risk and may have a negative effect on some measures of ERT efficacy. Inconsistencies in the identified data were likely driven by study design differences, including prior ERT exposure, follow-up time, and ADA assessment protocols. Additional prospective studies with standardized ADA assessments and accounting for patient baseline characteristics and disease severity, are needed to better understand the clinical implications of ADA formation on ERT outcomes, including an assessment of causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04438-8","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:55:37Z","timestamp":1784228137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the relationship between antidrug antibodies and efficacy and safety outcomes in patients with Fabry disease receiving enzyme replacement therapy: a systematic literature review"],"prefix":"10.1186","volume":"21","author":[{"given":"Patricio","family":"Aguiar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Bernat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-9173","authenticated-orcid":false,"given":"Derralynn","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"2","key":"4438_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/cge.13546","volume":"96","author":"DP Germain","year":"2019","unstructured":"Germain DP, Fouilhoux A, Decramer S, Tardieu M, Pillet P, Fila M, et al. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet. 2019;96(2):107\u201317. https:\/\/doi.org\/10.1111\/cge.13546.","journal-title":"Clin Genet"},{"key":"4438_CR2","unstructured":"European Medicines Agency. Summary of product characteristics: fabrazyme 35 mg powder for concentrate for solution for infusion. First authorized: August 3, 2001. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fabrazyme-epar-product-information_en.pdf."},{"key":"4438_CR3","unstructured":"US Food and Drug Administration. Prescribing information: fABRAZYME (agalsidase beta) for injection, for intravenous use. First authorized: 2003 [https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103979s5309lbl.pdf]."},{"key":"4438_CR4","unstructured":"European Medicines Agency. Summary of product characteristics: replagal 1 mg\/ml concentrate for solution for infusion. First authorized: April 3, 2001. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/replagal-epar-product-information_en.pdf."},{"key":"4438_CR5","unstructured":"European Medicines Agency. Summary of product characteristics: elfabrio 2 mg\/mL concentrate for solution for infusion. First authorized: May 4, 2023. https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/elfabrio-epar-product-information_en.pdf."},{"key":"4438_CR6","unstructured":"US Food and Drug Administration. Prescribing information: eLFABRIO (pegunigalsidase alfa-iwxj) injection, for intravenous use. First authorized: 2023 [https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761161s000lbl.pdf]."},{"key":"4438_CR7","unstructured":"Generics and Biosimilars Initiative (GaBi). News report: Argentina approves the first biosimilar agalsidase beta for Fabry disease [https:\/\/gabionline.net\/biosimilars\/news\/argentina-approves-the-first-biosimilar-agalsidase-beta-for-fabry-disease."},{"key":"4438_CR8","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","volume":"11","author":"A Vaisman-Mentesh","year":"2020","unstructured":"Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol. 2020;11:1951. https:\/\/doi.org\/10.3389\/fimmu.2020.01951.","journal-title":"Front. Immunol"},{"issue":"17","key":"4438_CR9","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s40265-021-01621-y","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders M, Brand E. Mechanisms of neutralizing anti-drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in Fabry disease. Drugs. 2021;81(17):1969\u201381. https:\/\/doi.org\/10.1007\/s40265-021-01621-y.","journal-title":"Drugs"},{"issue":"12","key":"4438_CR10","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1681\/ASN.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Neusser LP, Rudnicki M, Nordbeck P, Canaan-Kuhl S, Nowak A, et al. Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease. JASN. 2018;29(12):2879\u201389. https:\/\/doi.org\/10.1681\/ASN.2018070740.","journal-title":"JASN"},{"issue":"1","key":"4438_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J Am Soc Nephrol. 2016;27(1):256\u201364. https:\/\/doi.org\/10.1681\/ASN.2014121226.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"4438_CR12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","volume":"12","author":"O Lidove","year":"2010","unstructured":"Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, et al. Effects of enzyme replacement therapy in Fabry disease\u2014A comprehensive review of the medical literature. Genet Med. 2010;12(11):668\u201379. https:\/\/doi.org\/10.1097\/GIM.0b013e3181f13b75.","journal-title":"Genet Med"},{"issue":"4","key":"4438_CR13","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CEM, Donker-Koopman WE, Strijland A, Aerts JMFG. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004;66(4):1589\u201395. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00924.x.","journal-title":"Kidney Int"},{"issue":"16","key":"4438_CR14","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.3390\/ijms21165784","volume":"21","author":"van der Veen Sj","year":"2020","unstructured":"van der Veen Sj, Vlietstra WJ, van Dussen L, van Kuilenburg Abp, Dijkgraaf MGW, Lenders M, et al. Predicting the development of anti-drug antibodies against recombinant alpha-galactosidase a in male patients with classical Fabry disease. IJMS. 2020;21(16):5784. https:\/\/doi.org\/10.3390\/ijms21165784.","journal-title":"IJMS"},{"issue":"1","key":"4438_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13023-025-03705-4","volume":"20","author":"JF G\u00f3mez-Cerezo","year":"2025","unstructured":"G\u00f3mez-Cerezo JF, Fern\u00e1ndez-Mart\u00edn J, Barba-Romero M, S\u00e1nchez-Mart\u00ednez R, Hermida-Ameijeiras A, Camprodon-G\u00f3mez M, et al. Current status of the immunogenicity of enzyme replacement therapy in Fabry disease. Orphanet J Rare Dis. 2025;20(1):253. https:\/\/doi.org\/10.1186\/s13023-025-03705-4.","journal-title":"Orphanet J Rare Dis"},{"key":"4438_CR16","unstructured":"NICE. The social care guidance manual NICE process and methods. PMG10. Appendix C methodology checklist: randomised controlled trials. Published: 30 April 2013 (Last updated: 01 July 2016). [https:\/\/www.nice.org.uk\/process\/pmg10\/chapter\/appendix-c-methodology-checklist-randomised-controlled-trials#notes-on-use-of-methodology-checklist-randomised-controlled-trials."},{"key":"4438_CR17","unstructured":"Critical Appraisal Skills Programme. CASP checklist: cASP randomised controlled trial checklist. [https:\/\/casp-uk.net\/casp-tools-checklists\/randomised-controlled-trial-rct-checklist\/."},{"issue":"3","key":"4438_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","volume":"105","author":"WR Wilcox","year":"2012","unstructured":"Wilcox WR, Linthorst GE, Germain DP, Feldt-Rasmussen U, Waldek S, Richards SM, et al. Anti-\u03b1-galactosidase a antibody response to agalsidase beta treatment: data from the Fabry registry. Mol Genet Metab. 2012;105(3):443\u201349. https:\/\/doi.org\/10.1016\/j.ymgme.2011.12.006.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"4438_CR19","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/jmg-2023-109445","volume":"61","author":"EL Wallace","year":"2024","unstructured":"Wallace EL, Goker-Alpan O, Wilcox WR, Holida M, Bernat J, Longo N, et al. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. J Med Genet. 2024;61(6):520\u201330. https:\/\/doi.org\/10.1136\/jmg-2023-109445.","journal-title":"J Med Genet"},{"key":"4438_CR20","doi-asserted-by":"publisher","unstructured":"Vedder AC, Linthorst GE, Houge G, Groener JEM, Ormel EE, Bouma BJ, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg. PLoS One. 2007;2(7):e598. https:\/\/doi.org\/10.1371\/journal.pone.0000598.","DOI":"10.1371\/journal.pone.0000598"},{"issue":"3","key":"4438_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","volume":"94","author":"AC Vedder","year":"2008","unstructured":"Vedder AC, Breunig F, Donker-Koopman WE, Mills K, Young E, Winchester B, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab. 2008;94(3):319\u201325. https:\/\/doi.org\/10.1016\/j.ymgme.2008.03.003.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4438_CR22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ymgme.2018.11.008","volume":"126","author":"van der Veen Sj","year":"2019","unstructured":"van der Veen Sj, van Kuilenburg Abp, Hollak CEM, Kaijen PHP, Voorberg J, Langeveld M, et al. Antibodies against recombinant alpha-galactosidase a in Fabry disease: subclass analysis and impact on response to treatment. Mol Genet Metab. 2019;126(2):162\u201368. https:\/\/doi.org\/10.1016\/j.ymgme.2018.11.008.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4438_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2021.12.004","volume":"135","author":"van der Veen Sj","year":"2022","unstructured":"van der Veen Sj, Korver S, Hirsch A, Hollak CEM, Wijburg FA, Brands MM, et al. Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression. Mol Genet Metab. 2022;135(2):163\u201369. https:\/\/doi.org\/10.1016\/j.ymgme.2021.12.004.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4438_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","volume":"1812","author":"van Breemen Mj","year":"2011","unstructured":"van Breemen Mj, Rombach SM, Dekker N, Poorthuis BJ, Linthorst GE, Zwinderman AH, et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Et Biophys Acta (BBA) - Mol Basis Disease. 2011;1812(1):70\u201376. https:\/\/doi.org\/10.1016\/j.bbadis.2010.09.007.","journal-title":"Biochim Et Biophys Acta (BBA) - Mol Basis Disease"},{"issue":"5","key":"4438_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/14740338.2021.1891221","volume":"20","author":"M Tsurumi","year":"2021","unstructured":"Tsurumi M, Suzuki S, Hokugo J, Ueda K. Long-term safety and efficacy of agalsidase beta in Japanese patients with Fabry disease: aggregate data from two post-authorization safety studies. Expert Opin Drug Saf. 2021;20(5):589\u2013601. https:\/\/doi.org\/10.1080\/14740338.2021.1891221.","journal-title":"Expert Opin Drug Saf"},{"key":"4438_CR26","doi-asserted-by":"publisher","first-page":"100650","DOI":"10.1016\/j.ymgmr.2020.100650","volume":"25","author":"T Tsukimura","year":"2020","unstructured":"Tsukimura T, Tayama Y, Shiga T, Hirai K, Togawa T, Sakuraba H. Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy. Mol Genet Metab Rep. 2020;25:100650. https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100650.","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"4438_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ymgme.2012.12.005","volume":"108","author":"BE Smid","year":"2013","unstructured":"Smid BE, Hoogendijk SL, Wijburg FA, Hollak CE, Linthorst GE. A revised home treatment algorithm for Fabry disease: influence of antibody formation. Mol Genet Metab. 2013;108(2):132\u201337. https:\/\/doi.org\/10.1016\/j.ymgme.2012.12.005.","journal-title":"Mol Genet Metab"},{"key":"4438_CR28","doi-asserted-by":"publisher","unstructured":"Rombach SM, Aerts JMFG, Poorthuis BJHM, Groener JEM, Donker-Koopman W, Hendriks E, et al. Long-term effect of antibodies against infused alpha-galactosidase a in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One. 2012;7(10):e47805. https:\/\/doi.org\/10.1371\/journal.pone.0047805.","DOI":"10.1371\/journal.pone.0047805"},{"key":"4438_CR29","doi-asserted-by":"publisher","unstructured":"Riccio E, Zanfardino M, Franzese M, Capuano I, Buonanno P, Ferreri L, et al. Stepwise shortening of agalsidase beta infusion duration in Fabry disease: clinical experience with infusion rate escalation protocol. Molec Gen & Gen Med. 2021;9(5):e 1659. https:\/\/doi.org\/10.1002\/mgg3.1659.","DOI":"10.1002\/mgg3.1659"},{"issue":"3","key":"4438_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","volume":"92","author":"T Ohashi","year":"2007","unstructured":"Ohashi T, Sakuma M, Kitagawa T, Suzuki K, Ishige N, Eto Y. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. Mol Genet Metab. 2007;92(3):271\u201373. https:\/\/doi.org\/10.1016\/j.ymgme.2007.06.013.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4438_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13023-018-0877-4","volume":"13","author":"W Mauhin","year":"2018","unstructured":"Mauhin W, Lidove O, Amelin D, Lamari F, Caillaud C, Mingozzi F, et al. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY. Orphanet J Rare Dis. 2018;13(1):127. https:\/\/doi.org\/10.1186\/s13023-018-0877-4.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"4438_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/GIM.0b013e3181981d82","volume":"11","author":"JC Lubanda","year":"2009","unstructured":"Lubanda JC, Anijalg E, Bzduch V, Thurberg BL, Benichou B, Tylki-Szymanska A. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Genet Med. 2009;11(4):256\u201364. https:\/\/doi.org\/10.1097\/GIM.0b013e3181981d82.","journal-title":"Genet Med"},{"issue":"1","key":"4438_CR33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13023-023-02937-6","volume":"18","author":"A Linhart","year":"2023","unstructured":"Linhart A, Dost\u00e1lov\u00e1 G, Nicholls K, West ML, T\u00f8ndel C, Jovanovic A, et al. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. Orphanet J Rare Dis. 2023;18(1):332. https:\/\/doi.org\/10.1186\/s13023-023-02937-6.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"4438_CR34","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/jmedgenet-2020-106874","volume":"58","author":"M Lenders","year":"2021","unstructured":"Lenders M, Nordbeck P, Canaan-Kuhl S, Kreul L, Duning T, Lorenz L, et al. Treatment switch in Fabry disease - a matter of dose? J Med Genet. 2021;58(5):342\u201350. https:\/\/doi.org\/10.1136\/jmedgenet-2020-106874.","journal-title":"J Med Genet"},{"issue":"4","key":"4438_CR35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40268-021-00361-4","volume":"21","author":"A Khan","year":"2021","unstructured":"Khan A, Sirrs SM, Bichet DG, Morel CF, Tocoian A, Lan L, et al. The safety of agalsidase alfa enzyme replacement therapy in Canadian patients with Fabry disease following implementation of a bioreactor process. Drugs R D. 2021;21(4):385\u201397. https:\/\/doi.org\/10.1007\/s40268-021-00361-4.","journal-title":"Drugs R D"},{"key":"4438_CR36","doi-asserted-by":"publisher","unstructured":"Holida M, Linhart A, Pisani A, Longo N, Eyskens F, Goker-Alpan O, et al. A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. J Inher Metab Disea. 2025;48(1):e12795. https:\/\/doi.org\/10.1002\/jimd.12795.","DOI":"10.1002\/jimd.12795"},{"issue":"1","key":"4438_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","volume":"96","author":"B Benichou","year":"2009","unstructured":"Benichou B, Goyal S, Sung C, Norfleet AM, O\u2019Brien F. A retrospective analysis of the potential impact of IgG antibodies to agalsidase \u03b2 on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab. 2009;96(1):4\u201312. https:\/\/doi.org\/10.1016\/j.ymgme.2008.10.004.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"4438_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","volume":"55","author":"M Arends","year":"2018","unstructured":"Arends M, Biegstraaten M, Wanner C, Sirrs S, Mehta A, Elliott PM, et al. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet. 2018;55(5):351\u201358. https:\/\/doi.org\/10.1136\/jmedgenet-2017-104863.","journal-title":"J Med Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04438-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04438-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04438-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:12:42Z","timestamp":1787569962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04438-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4438"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04438-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JAB receives research support from Avrobio, BioMarin Pharmaceutical, Chiesi Farmaceutici, Denali Therapeutics, Idorsia Pharmaceuticals, Pfizer, Protalix BioTherapeutics, Sangamo Therapeutics, Sanofi, Takeda, and Travere Therapeutics, and has participated in advisory boards for Chiesi and Mirum Pharmaceuticals. PA receives grant\/research support from Takeda, and speaker\/travel honoraria from Alexion, Amicus Therapeutics, BioMarin, Chiesi, Sanofi-Genzyme, Takeda, and Ultragenyx. DH has received honoraria for speaking and consulting fees for advisory boards from AceLinkAcelink, Amicus, Chiesi, Freeline, Uniqure, Sangamo, Sanofi, and Takeda, administered through University College London consultants, and used in part to support research in lysosomal storage diseases.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"297"}}